TITLE:
A Study of Disease Progression and Anti-HIV Treatments

CONDITION:
HIV Infections

INTERVENTION:
Lamivudine

SUMMARY:

      To determine the influence of virus load, CD4 count, biologic phenotype, and presence of
      symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen.
      PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment
      for 6 months.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Prior participation on protocol ACTG 175.

        PER AMENDMENT 8/27/96:

          -  Patients must be on study/on treatment at the time the protocol study treatment is
             extended.
      
